Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Alzheimer’s Disease Therapeutics: Alternatives to Amyloid 2021

Alzheimer’s Disease Therapeutics: Alternatives to Amyloid 2021

Friday, December 3, 2021, 10:00 AM - 5:00 PM EST

Webinar

Presented By

The Brain and Behavior Discussion Group

The New York Academy of Sciences

 

Alzheimer’s disease (AD) continues to be on the rise in the US and worldwide. Currently, more than six million Americans suffer AD while Alzheimer’s and dementia deaths have increased 16 % during the COVID-19 pandemic. Despite this, developing effective therapeutics has proven to be challenging and with the FDA’s recent delay of Aducanumab’s approval process, there are still no approved disease-modifying therapeutics for this devastating neurodegenerative disorder. The results from targeting amyloid as a disease driver —which at best can be viewed as mixed, and at worst as disappointing— highlight the importance of identifying alternative drug targets. In addition, there is great need for developing new tools for early detection and prediction of disease onset. This one-day symposium will feature the latest research on topics including neurogenesis, neuroprotection, lifestyle factors, and brain-peripheral organ interaction, with an emphasis on showcasing promising avenues for therapeutic development in AD.

Call for Abstracts

You are invited to submit a poster abstract which will be displayed virtually on our website. See here for submission guidelines. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Friday, September 24, 2021.

Deadline:
165
days
left

Scientific Organizing Committee

Howard Fillit, MD
Howard Fillit, MD

Alzheimer's Drug Discovery Foundation

Lisa Mosconi, PhD
Lisa Mosconi, PhD

Weill Cornell Medical College

Rudolph Tanzi, PhD
Rudolph Tanzi, PhD

Harvard Medical School

Sonya Dougal, PhD
Sonya Dougal, PhD

The New York Academy of Sciences

Barbara Knappmeyer, PhD
Barbara Knappmeyer, PhD

The New York Academy of Sciences